Chiesi snags Atopix in potential $80M milestone-based deal
By Nuala Moran
Monday, November 21, 2016
LONDON – U.K. allergy specialist Atopix Therapeutics Ltd. is being acquired by the privately held Chiesi Farmaceutica SpA, in a milestone-based deal that could exceed €75 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.